Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay

Ermel, Aaron; Qadadri, Brahim; Morishita, Atsushi; Miyagawa, I.; Yamazaki, G.; Weaver, Bree; Tu, Wanzhu; Tong, Yan; Randolph, Melissa; Cramer, Harvey; Brown, Darron R.

doi:10.1016/j.jviromet.2010.07.016

Cited by 23 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this assay, the probe used to detect HPV 52 amplicons also hybridizes to amplicons of HPV types 33, 35, and 58. 22 Thus, reported values for HPV 52 indicate detection of HPV 52 DNA as per the algorithm provided by the manufacturer (that is, HPV 52 only when HPV 33, 35, or 58 were not detected). Because pre and post HPV surveillance samples were evaluated by using the same methods but in 2 different laboratories, we performed a validation analysis comparing results for a random sample of 96 swabs from the prevaccination surveillance study to ensure that results were consistent.…”

Section: Study Proceduresmentioning

confidence: 99%

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

et al. 2012

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT:Clinical trials have demonstrated that prophylactic human papillomavirus (HPV) vaccines are highly effective in preventing HPV infection, but the impact of vaccination on HPV prevalence rates in real-world, community settings is uncertain. WHAT THIS STUDY ADDS:This study provides evidence of a substantial decrease in the prevalence of vaccine-type HPV among young women and evidence of herd protection in a community only 4 years after the quadrivalent HPV vaccine was licensed.abstract OBJECTIVES: The aims of this study were to compare prevalence rates of human papillomavirus (HPV) in young women before and after HPV vaccine introduction to determine the following: (1) whether vaccine-type HPV infection decreased, (2) whether there was evidence of herd protection, and (3) whether there was evidence for typereplacement (increased prevalence of nonvaccine-type HPV). METHODS:Young women 13 to 26 years of age who had had sexual contact were recruited from 2 primary care clinics in 2006-2007 for a prevaccination surveillance study (N = 368, none were vaccinated) and 2009-2010 for a postvaccination surveillance study (N = 409, 59% were vaccinated). Participants completed a questionnaire and were tested for cervicovaginal HPV DNA. HPV prevalence rates were compared in the pre-versus postsurveillance studies by using x 2 tests. Propensity score weighting was used to balance differences in covariates between the 2 surveillance studies. RESULTS:The mean age was ∼19 years for both groups of participants and most were African American and non-Hispanic. After propensity score weighting, the prevalence rate for vaccine-type HPV decreased substantially (31.7%-13.4%, P , .0001). The decrease in vaccine-type HPV not only occurred among vaccinated (31.8%-9.9%, P , .0001) but also among unvaccinated (30.2%-15.4%, P , .0001) postsurveillance study participants. Nonvaccine-type HPV increased (60.7%-75.9%, P , .0001) for vaccinated postsurveillance study participants.CONCLUSIONS: Four years after licensing of the quadrivalent HPV vaccine, there was a substantial decrease in vaccine-type HPV prevalence and evidence of herd protection in this community. The increase in nonvaccine-type HPV in vaccinated participants should be interpreted with caution but warrants further study.

show abstract

Section: Study Proceduresmentioning

confidence: 99%

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Therefore, it is of considerable clinical value to establish a reliable and convenient method to detect and genotype HPV [5]. Currently, being the only FDA-approved (the U.S. Food and Drug Administration) commercially available method for the detection of HPV DNA, the well-established Hybrid Capture II system (HC-II) has been proven to be a sensitive and reliable assay, which can detect 13 types of carcinogenic-HPV types or 5 types of low-risk HPV in a single test [6, 7].…”

Section: Introductionmentioning

confidence: 99%

“…Currently, being the only FDA-approved (the U.S. Food and Drug Administration) commercially available method for the detection of HPV DNA, the well-established Hybrid Capture II system (HC-II) has been proven to be a sensitive and reliable assay, which can detect 13 types of carcinogenic-HPV types or 5 types of low-risk HPV in a single test [6, 7]. However, its main undeniable limitation is that HC-II cannot distinguish between different HPV genotypes definitely [5, 8]. Recently, a new HPV-genotyping method combining two advanced techniques, the flow-through hybridization and gene chip (HybriMax) has been used to detect and genotype HPV, which can distinguish 21 different types of HPV DNA in a single test and diagnose multiple infections [9–11].…”

Section: Introductionmentioning

confidence: 99%

Sensitive HPV Genotyping Based on the Flow-Through Hybridization and Gene Chip

Tao

Zheng

Wang

et al. 2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Persistent infection of high-risk human papillomavirus (HPV) has been recognized as the direct cause of cervical carcinoma. Therefore, detection and genotyping of HPV are important to cervical-cancer screening. In this study, we have evaluated the efficacy of flow-through hybridization and gene chip (HybriMax) on HPV genotyping through comparison of the results with Hybrid Capture II (HC-II) and in situ hybridization (ISH). 591 women were classified into 6 groups according to their histological diagnoses. The overall accordance rate on 13 types of HPV genotypes between HybriMax and HC-II were 92.5% and 100% in the cancer group. The overall accordance was excellent with the Kappa index (KI) of 0.814. The value of KI in each group was 0.750 (normal cytological diagnosis), 0.781 (chronic cervicitis), 0.80 (condyloma acuminatum), 0.755 (cervical intraepithelial neoplasia (CIN) I), 0.723 (CIN II), and 0.547 (CIN III) (0.75 > KI > 0.4, good; KI ≥ 0.75, excellent). The 10 most common HPV subtype detected by HybriMax were 16, 52/58, 18, 33, 31, 81, 53, 68, and 66 in patients, and 16, 68, 18, 52, 58, 11, 53, 31/39, and 33 in normal controls. In conclusion, HybriMax is an efficient method for HPV genotyping and more suitable for clinical use.

show abstract

“…Thus, the region of genome DNA to be synthesized is defined by the primers, which anneal specifically to their complementary sequences in the template strand, limiting the DNA fragment to the one that needs to be amplified. 9,10,19,20 In this study, the resulting PCR product was submitted to electrophoresis (semiquantitative analysis) in 1.5% agarose gel and stained with ethidium bromide. The intensity of the bands of pure and diluted samples was compared with those presented by the cells, providing the viral load value.…”

Section: Methodsmentioning

confidence: 99%

High-Power Diode Laser Versus Electrocautery Surgery on Human Papillomavirus Lesion Treatment

Baeder¹,

Santos²,

Pelino³

et al. 2012

Journal of Craniofacial Surgery

View full text Add to dashboard Cite

The use of high-power lasers has facilitated and improved human papillomavirus (HPV) treatment protocols and has also become very popular in recent years. This application has been more frequently used in hospitals, especially in gynecology. The present study aimed to evaluate the effects of high-power diode laser to remove oral lesions caused by HPV and the consequent effects on virus load following the wound tissue healing process compared with one of the most conventional surgical techniques involving electrocautery. Surgeries were performed on 5 patients who had 2 distinct lesions caused by HPV. All patients were submitted to both electrocautery and high-power diode laser. Following a 20-day period, when the area was healed, sample material was collected through curettage for virus load quantitative analysis.Observation verified the presence of virus in all the samples; however, surgeries performed with the laser also revealed a significant reduction in virus load per cell compared with those performed with electrocautery. The ease when handling the diode laser, because of the flexibility of its fibers and precision of its energy delivery system, provides high-accuracy surgery, which facilitates the treatment of large and/or multifocal lesions. The use of high-power diode laser is more effective in treatment protocols of lesions caused by HPV.

show abstract

Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay

Cited by 23 publications

References 24 publications

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

Sensitive HPV Genotyping Based on the Flow-Through Hybridization and Gene Chip

High-Power Diode Laser Versus Electrocautery Surgery on Human Papillomavirus Lesion Treatment

Contact Info

Product

Resources

About